Nasus Pharma Ltd. reported a net loss of $5.9 million for the six months ended June 30, 2026, compared to a $1.3 million loss in the prior year period. The company raised $15.0 million in gross proceeds from a private placement completed on February 13, 2026, bringing its cash and short-term deposits to approximately $11.9 million as of June 30, 2026. Management appointed Brendan O’Grady as Chief Executive Officer effective July 27, 2026. Clinically, the company plans to initiate a pivotal Phase 3 study for its lead candidate NS002 (intranasal epinephrine) in the fourth quarter of 2026 and expects to begin first-in-human trials for NS003 (ondansetron) shortly. The filing includes unaudited interim financial statements, management discussion, and a press release detailing these results and updates. Nasus Pharma Ltd. is a clinical-stage specialty pharmaceutical company focused on developing innovative intranasal powder-based therapies.
